Our headquarters are located at 14755 Preston Road, Suite 105, Dallas, TX 75254. The main office phone number is (972) 687-7250.
Our common stock is traded on the NASDAQ Capital Market under the symbol SWKH. Our CUSIP number is 78501P203.
SWK’s fiscal year end is December 31st.
462 South 4th Street
Louisville, KY 40202
Outside Legal Counsel: Gray Reed (1601 Elm St #4600, Dallas, TX 75201, 214-954-4135)
Auditors: BPM LLP
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information section of our Investor Relations webpage or directly from the SEC at www.sec.gov.
SWK Holdings Corporation was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, the Company commenced its life science focused specialty finance business. In August 2019, the Company commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business with the acquisition of Enteris BioPharma, Inc..
Tiberend Strategic Advisors is SWK’s investor relations firm. For additional information, please contact:
Tiberend Strategic Advisors, Inc.
SWK’s officers and directors can be found in the “About SWK” section of our website.